Clinical Trials
16 trialsNCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
NCT03539744 2025-06-19
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
AbbVie
Phase 3 Active not recruiting
NCT03578081 2025-04-06
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT03839940 2025-01-29
MIST
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT02393859 2024-05-29
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Completed
NCT01788020 2024-05-13
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
University of Ulm
Phase 3 Completed
NCT05872893 2023-07-21
Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone
Immune Oncology Research Institute
Phase 3 Unknown
NCT03033511 2021-07-29
MERU
AbbVie
Phase 3 Terminated
NCT01661335 2021-03-23
Efficacy of Aprepitant (Emend®) in Children
University of Oklahoma
Phase 3 Completed
NCT00016380 2020-04-03
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
Canadian Cancer Trials Group
Phase 3 Completed
NCT03334487 2018-12-26
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
AbbVie
Phase 3 Withdrawn
NCT02203253 2016-08-24
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting
China Medical University, China
Phase 3 Completed
NCT00083551 2015-11-23
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
University of Arkansas
Phase 3 Completed
NCT00891761 2015-04-17
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
GlaxoSmithKline
Phase 3 Withdrawn
NCT00813150 2014-08-15
Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma
Janssen-Cilag G.m.b.H
Phase 3 Completed
NCT00152867 2012-06-28
Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy
University Health Network, Toronto
Phase 3 Completed